We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00413751
First Posted: December 20, 2006
Last Update Posted: December 20, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Walter Reed Army Medical Center
December 19, 2006
December 20, 2006
December 20, 2006
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
Not Provided
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Not Provided
Observational
Time Perspective: Longitudinal
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Healthy
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
Not Provided
Not Provided

Inclusion Criteria:

  • Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

  • Patients not meeting above stated age criteria
  • Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
  • History of serious ocular, neurological, cardiovascular disease
  • History of severe systemic disease
  • History of arrhythmias or high blood pressure
  • Patients currently taking any type of ocular or systemic medications except multivitamins.
  • Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00413751
WRAMC WU #03-23004
Not Provided
Not Provided
Not Provided
Not Provided
Walter Reed Army Medical Center
Not Provided
Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center
Walter Reed Army Medical Center
December 2006